- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Agena Bioscience Launches CFTR 100+ Panel for Expanded Genetic Variant Analysis
New multiplex assay offers broader coverage of CFTR variants to align with updated professional recommendations.
Mar. 31, 2026 at 3:19am
Got story updates? Submit your updates here. ›
An abstract, visually striking representation of the genetic complexities underlying cystic fibrosis, as Agena Bioscience expands its CFTR variant analysis capabilities.San Diego TodayAgena Bioscience, a provider of molecular genomics solutions, has announced the launch of the CFTR 100+ Panel, a multiplex genotyping solution designed to provide expanded coverage of CFTR variants on the MassARRAY® System. The panel includes all variants recommended in the 2023 update from the American College of Medical Genetics and Genomics (ACMG) for carrier screening, along with additional CFTR variants of interest.
Why it matters
The CFTR gene is associated with cystic fibrosis and related genetic conditions. As professional recommendations have evolved to support broader variant representation across diverse populations, laboratories have sought scalable solutions capable of interrogating expanded CFTR variant sets. The CFTR 100+ Panel is designed to help labs align with current guidance while maintaining efficient, high-throughput workflows.
The details
The CFTR 100+ Panel enables simultaneous analysis of more than 100 CFTR variants within a single multiplex assay format, built on Agena's MALDI-TOF mass spectrometry–based MassARRAY® System. The system is widely used in population-scale molecular programs, offering reproducibility, scalability, and streamlined assay design.
- The CFTR 100+ Panel was launched on March 31, 2026.
The players
Agena Bioscience
A global provider of molecular genomics solutions and the developer of the CFTR 100+ Panel.
American College of Medical Genetics and Genomics (ACMG)
The professional organization that issued the 2023 update on CFTR variant recommendations for carrier screening.
MassARRAY® System
Agena's MALDI-TOF mass spectrometry platform that the CFTR 100+ Panel is built upon.
What they’re saying
“With evolving CFTR variant recommendations, laboratories are reassessing panel content to ensure alignment with current standards. The CFTR 100+ Panel provides expanded, guideline-aligned variant coverage while leveraging the established workflow and throughput capabilities of the MassARRAY® System.”
— Darryl Irwin, VP of Scientific Affairs at Agena Bioscience
What’s next
The CFTR 100+ Panel is currently available for research use only (RUO). Agena Bioscience plans to work with laboratories to implement the expanded panel and support their efforts to align with updated CFTR variant recommendations.
The takeaway
The launch of the CFTR 100+ Panel reflects the evolving needs of molecular genomics laboratories to analyze a broader set of genetic variants associated with cystic fibrosis and related conditions. By providing a scalable, high-throughput solution that aligns with current professional guidelines, Agena Bioscience aims to enable more comprehensive genetic testing and screening programs.
